Gilead Sciences Inc. Has $360,000 Holdings in Barinthus Biotherapeutics PLC Sponsored ADR $BRNS

Key Points

• Gilead Sciences Inc. reduced its stake in Barinthus Biotherapeutics by 40.4%, now holding 369,855 shares, which represents about 0.0% of its overall portfolio.
• Barinthus Biotherapeutics reported an EPS of ($0.52) for the last quarter, missing consensus estimates, reflecting ongoing challenges as it develops immunotherapeutic candidates.
• The company's stock opened at $1.26 with a 1-year high of $2.92 and a low of $0.64, indicating volatility in its market performance.

Gilead Sciences Inc. decreased its position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Free Report) by 40.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 369,855 shares of the company's stock after selling 250,496 shares during the quarter. Barinthus Biotherapeutics comprises approximately 0.0% of Gilead Sciences Inc.'s investment portfolio, making the stock its 14th biggest holding. Gilead Sciences Inc. owned about 0.92% of Barinthus Biotherapeutics worth $360,000 at the end of the most recent reporting period.

Separately, HighTower Advisors LLC bought a new position in Barinthus Biotherapeutics during the 1st quarter worth approximately $36,000. Institutional investors own 25.20% of the company's stock.

Barinthus Biotherapeutics Stock Up 2.1%

Barinthus Biotherapeutics stock traded up $0.0250 during midday trading on Friday, hitting $1.21. 4,729 shares of the stock were exchanged, compared to its average volume of 509,224. The company has a fifty day simple moving average of $1.21 and a two-hundred day simple moving average of $1.02. Barinthus Biotherapeutics PLC Sponsored ADR has a 52 week low of $0.64 and a 52 week high of $2.92. The stock has a market capitalization of $48.81 million, a PE ratio of -0.70 and a beta of -0.73.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.23). As a group, equities research analysts anticipate that Barinthus Biotherapeutics PLC Sponsored ADR will post -1.38 EPS for the current fiscal year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.